Oncternal Therapeutics, Inc. Announces Executive Appointments
September 09, 2019 at 08:00 am EDT
Share
Oncternal Therapeutics, Inc. announced the appointment of Gunnar Kaufmann, Ph.D., as Chief Scientific Officer and Igor Bilinsky, Ph.D., as Chief Business Officer. Prior to joining Oncternal, Dr. Kaufmann served as Senior Vice President, Immunotherapy, Head of Research and Global Partnerships at Sorrento Therapeutics, Inc. Dr. Kaufmann was previously a faculty member at The Scripps Research Institute and still serves as Adjunct Assistant Professor in the Departments of Chemistry and Immunology and Microbial Science. Dr. Bilinsky, who has more than 20 years of experience as a senior executive and consultant to the biotechnology industry, will be responsible for strategic planning and advancing corporate and business development initiatives at Oncternal. Dr. Bilinsky formerly served as Chief Operating Officer of AmpliPhi Biosciences Corporation, a biotechnology company developing targeted therapies for patients with life-threatening bacterial infections.
Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of oncology therapies for the treatment of patients with cancers that have critical unmet medical needs. The Companyâs product candidates include ONCT-534, ONCT-808, Zilovertamab, and ONCT-216. ONCT-534 is a dual-action androgen receptor inhibitor (DAARI), for the treatment of advanced castration-resistant prostate cancer (CRPC) and other androgen receptor (AR) driven diseases. ONCT-808 is an autologous chimeric antigen receptor (CAR-T) therapy that targets ROR1 for the treatment of hematologic malignancies and solid tumors. Zilovertamab is an investigational, humanized, monoclonal antibody designed to inhibit the function of Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1). Zilovertamab has been evaluated in an investigator-initiated Phase 1b study of zilovertamab in combination with docetaxel in patients with mCRPC.